Fed Circuit once again instructs on enablement of Rx claims
· mari serebrov
Source Summary
A federal jury was wrong when it determined that Astrazeneca plc should pay Wyeth, a Pfizer Inc. unit, $107.5 million in damages for infringing two cancer patents, the U.S. Court of Appeals for the Federal Circuit said in a recent precedential decision.
Advertisement